News & Events

 

May 30th 2009

- Semafore's SF1126, a vascular targeted pan-PI3K/mTOR inhibitor, is well tolerated and demonstrates activity in Phase I solid tumor patients (ASCO 2009)

March 17th 2009

- Semafore Achieves a Preclinical Milestone with SF2626, a PI3K-MEK Dual Pathway Kinase Inhibitor

December 1st 2008

- GEN report: Zeroing in on PI3K Pathway

December 1st 2008

- Semafore presents poster "Regulating the Critical PI3 Kinase & PTEN Cell Signals for Major Advances in Targeted Cancer Therapies" at the Cancer-Oncology Summit in Indianapolis, IN